Purpose: Patient-assessed health-related quality-of-life (HRQOL) scores, together with demographic and clinical factors in stage III non-small cell lung cancer (NSCLC) patients, are important prognostic factors for survival and may be helpful in determining thoracic radiotherapy (TRT) strategy. Methods: In a previously published randomized trial, 301 patients were treated with different palliative radiotherapy schedules, comparing short-term hypofractionated TRT (arm A: 17 Gy/2 fractions [n ϭ 105]) with more protracted TRT (arm B: 42 Gy/15 fractions [n ϭ 104]); arm C: 50 Gy/25 fractions [n ϭ 92]). Baseline HRQOL, demographic, and clinical data were available for all patients. All possible prognostic factors from univariate analysis were entered into the Cox multivariate regression model to identify variables of independent prognostic relevance. Results: Overall survival was similar, whereas long-term survival was restricted to higher-dose radiotherapy with 3-year survival rates of 1, 8, and 6% (p ϭ 0.40) and 5-year survival rates of 0, 4, and 3% (p ϭ 0.12) in arms A, B, and C, respectively. In univariate analysis, Karnofsky performance status, use of analgesics, and weight loss were highly significant non-HRQOL factors (p Ͻ 0.001), and physical function, appetite loss, cough, and pain were the most powerful HRQOL factors (p Ͻ 0.001). In multivariate analysis, appetite loss appeared as the most powerful independent prognostic indicator. In the group of patients treated with protracted fractionation (n ϭ 196), the 2-, 3-, and 5-year survival rates in patients with no appetite loss (n ϭ 95) were 22% (21/95), 12% (11/95), and 8% (8/95) compared with 3% (3/101), 1% (1/101), and 1% (1/101) in patients with appetite loss present at baseline (n ϭ 101).
D
uring the last decade, health-related quality-of-life (HRQOL) issues have been established as important endpoints in clinical trials. 1 Quality-of-life assessment should be patient-assessed using validated questionnaires including general health and disease-and symptom-specific questions. Traditionally, HRQOL has supplied important information in addition to clinical outcome measures such as tumor response and survival. For studies on noncurative therapies in cancer patients, HRQOL has emerged as one of the most import endpoints for treatment effect. 2 HRQOL data have been shown to supply significant prognostic information in a variety of cancers. 3, 4 In lung cancer, baseline HRQOL data are strong prognosticators in both curative and palliative settings. [5] [6] [7] [8] In advanced NSCLC patients, it has been shown that HRQOL assessments during the first 6 weeks of chemotherapy are good predictors for both response and survival. 9 Although there is an increasing use of chemotherapy in locally advanced non-small cell lung cancer (NSCLC), palliative thoracic radiotherapy (TRT) remains important for palliation of intrathoracic symptoms in patients progressing during chemotherapy or when chemotherapy is not indicated or feasible. Hypofractionated (10 -17 Gy) TRT and higher-dose TRT (40 -60 Gy) are equally effective in their palliative effects on disease-related symptoms. 10 -12 However, a Cochrane analysis gave evidence for a modestly increased survival (6% at 1 year and 3% at 2 years) in favor of higher-dose radiotherapy in patients with good performance status (PS) and localized disease. 13 In a study by the Norwegian Lung Cancer Study Group, 12 a trend to better 3-year survival in stage III patients with good PS (Karnofsky PS Ն80) was observed.
The aim of this study was to examine the predictive value of baseline HRQOL data in patients with stage III disease scheduled for palliative TRT, in comparison with demographic, clinical, and treatment variables. The research question is whether HRQOL data can be of help in the selection of hypofractionated versus higher-dose TRT in patients with locally advanced NSCLC.
MATERIALS AND METHODS

Patients and Staging
A total of 301 patients with stage III disease who completed baseline HRQOL questionnaires and were treated with three different palliative TRT regimens were included in this analysis. A complete description of the total study population and inclusion criteria has been published previously. 12 The general inclusion criteria were confirmed histology or cytology consistent with NSCLC, age Ն18, stage III disease, Karnofsky PS Ն40%, completed baseline HRQOL questionnaire, expected survival Ն2 months, and centrally located tumor causing airway symptoms or without symptoms but threatening central airways. Among patients with stage IIIA disease, traditionally with more favorable prognosis, only inoperable patients with poor prognostic factors such as tumor diameter Ն7 cm, Karnofsky PS Յ70%, or weight loss Ն10% during the last 6 months were eligible. Previous chemotherapy was allowed, but earlier TRT led to ineligibility.
At inclusion, all patients were staged based on physical and radiological examinations (chest x-ray and computed tomography of the chest including liver and adrenal glands). Cerebral computed tomography or cerebral magnetic resonance imaging and bone scans were performed only if symptoms. The patients were categorized according to the 1986 clinical stage classification. 14 Baseline laboratory determinants (cell counts, erythrocyte sedimentation rate, alkaline phosphatase, lactate dehydrogenase, gamma glutamyl transpeptidase, and neuron specific enolase) were registered, together with Karnofsky PS, use of analgesics and/or steroids, and weight loss during the last 6 months.
TRT
TRT was given as two opposing anterior-posterior fields individually encompassing the regional mediastinal lymph nodes and the primary tumor with a 1.5-to 2-cm margin. The following fractionation schemes were used: arm A, two fractions of 8.5 Gy on days 1 and 8 for a total dose of 17 Gy; arm B, 15 fractions of 2.8 Gy for a total dose of 42 Gy; and arm C, 25 fractions of 2 Gy for a total dose of 50 Gy. In arm B, a filter was inserted in the posterior field to reduce radiation dose to the spinal cord to 2.6 Gy per fraction, thereby not exceeding an equivalent dose value of 1180 ret. Using the cumulative radiation effect formula, 15 the radiobiological effects were equivalent in arms B and C. The maximal portal length, exposing the spinal cord, was set to 12 cm.
HRQOL
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire and the lung cancer-specific module (QLQ-LC13) were used to measure HRQOL. 16, 17 The core questionnaire incorporates five functional scales (physical, role, emotional, cognitive, social), three symptom scales (fatigue, nausea/vomiting, pain), a global health and overall quality-of-life scale, and five single items (dyspnea, appetite loss, sleep disturbance, constipation and diarrhea, and financial impact of the disease and its treatment). The QLQ-LC13 module contains items for measuring dyspnea, cough, hemoptysis, mucositis, dysphagia, peripheral neuropathy, alopecia, pain, and analgesic consumption/effect. All scales and single items were linearly transformed to a 0 to 100 scale, with a higher score on functional scales indicating a high degree of function and a higher score on the symptom scales indicating more symptoms.
Prognostic Factors
Clinical variables possibly predicting survival in NSCLC were categorized at baseline. Laboratory blood determinants were dichotomized according to normal and elevated values. Karnofsky PS status and weight loss were each divided into three different categories (Karnofsky PS 90 -100, Karnofsky PS 70 -80, and Karnofsky PS Յ60 for Karnofsky PS and none, Ͻ10%, and Ն10% for weight loss). Histology was categorized in squamous or nonsquamous differentiation, and use of analgesics and steroids were divided in used or not used.
The scores in the HRQOL scales or single symptoms are continuous variables and are not easy to interpretate in the clinic. Dichotomized HRQOL variables are more easily comprehensible and were chosen as the preferred presenting method in this report. The HRQOL baseline scores were dichotomized according to Ͻ median score or Ն median score in the functional scales and Յ median score or Ͼ median score in the symptom scales.
Statistical Analysis
The Cancer Research Trial Office at the University Hospital in Trondheim performed the randomization based on a block-randomization method. Baseline HRQOL data were calculated using group scores for the mean value of each variable. 18 Univariate survival analyses related to baseline HRQOL, demographic, and clinical factors were performed using the method of Kaplan-Meier. 19 Survival was determined on an intention-to-treat basis from the first day of TRT, and the log-rank test was applied for comparison of survival. All variables with p values of less than 0.10 in the univariate analysis were entered into the multivariate analysis using the proportional hazards model of Cox. 20 Probability for forward stepwise entry and removal was set at 0.05 and 0.10, respectively. The significance level was set at 0.05 using a twosided test.
RESULTS
Patient Population, Treatment, and Survival
disease who completed baseline HRQOL questionnaires constituted this study. Patient characteristics are presented in Table 1 . Females accounted for 23%, and the median age was 68 years (range, 41-88). The majority of patients were categorized as Karnofsky PS 70 -80. Only 7% had PS 60 or below. Close to one third had major (Ͼ10%) weight loss. There were no significant differences between the treatment arms regarding stage, histology, and lab tests. About half of the patients had squamous cell histology. Compliance of baseline HRQOL questionnaires was 99%, with equal distribution of baseline HRQOL scores in all treatment arms (data not shown).
Sixteen patients terminated TRT prematurely (one in arm A, eight in arm B, and eight in arm C [p ϭ 0.03]). Only six patients were treated with chemotherapy during followup, but none of these survived for more than 18 months. Other palliative therapies were irradiation to symptomatic metastatic sites and best supportive care.
All patients were followed until death or for at least 5 years. There was no significant difference in survival (p ϭ 0.53) between the treatment arms, as shown in Figure 1 . Median survival was 9.2, 7.5, and 7.5 months in arms A, B, and C, respectively. There was a trend towards more long-term survivors in arms B and C, even though this difference did not reach statistical significance. However, long-term survivors were almost exclusively treated within the prolonged fractionated treatment arms. The 3-and 5-year survival rates were 1 and 0% in arm A; 8 and 6% in arm B; and 4 and 3% in arm C.
Univariate Analysis
Univariate analysis results for baseline demographic, clinical, and laboratory values (non-HRQOL) are presented in Table 2 . No differences within stage IIIA and stage IIIB were revealed. Analysis of continuous and dichotomized HRQOL variables gave similar results. Because of the easier interpretation of dichotomized variables, the results from dichotomized scores are presented in Table 3 . Of 17 evaluated non-HRQOL factors, nine were statistically significant. The most prominent factors were Karnofsky PS (p Ͻ 0.0001, Figure 2 ), weight loss (p Ͻ 0.001), use of analgesics (p Ͻ 0.001), use of steroids (p Ͻ 0.01), white blood cell count (p Ͻ 0.01), and platelet count (p Ͻ 0.01). Of 16 different baseline HRQOL scores, all but one (cognitive function) were of possible prognostic relevance (p Ͻ 0.05). Appetite loss (p Ͻ 0.0001, Figure 3 ) and cough (p Ͻ 0.0001) were highly significant, and physical function, nausea and vomiting, pain, and hemoptysis also were strong indicators of survival (p Ͻ 0.001).
Multivariate Analysis
All statistically significant variables from the univariate analysis were included in a Cox multivariate regression analysis (11 non-HRQOL, 15 HRQOL variables [p Ͻ 0.10]). Because data were missing for 41 cases, 260 patients were included in this analysis. Appetite loss (p Ͻ 0.001), use of steroids (p ϭ 0.019), and role function (p ϭ 0.022) were found to independently predict survival, whereas physical function had borderline significance (Table 4) . Karnofsky PS, weight loss, and the other highly significant baseline HRQOL factors from the univariate analysis (nausea and vomiting, pain, cough, hemoptysis) did not reach statistical significance in this model.
Appetite loss was dichotomized in Յ median score versus Ͼ median score and emerged in this model as the most significant independent predictor for survival. Median score in the appetite scale was 0 (not at all). In that respect, any reported loss of appetite will indicate limited survival. Among those 196 patients treated with prolonged fractionation (arm B, arm C), the combined 2-, 3-, and 5-year survival rates were 12% (24/196), 6% (12/196) , and 5% (9/196). In comparison, the 2-, 3-, and 5-year survival rates in patients with no appetite loss at baseline treated with protracted fractionation (n ϭ 95) were 22% (21/95), 12% (11/95), and 8% (8/95), respectively.
DISCUSSION
The present study was carried out to identify possible prognostic indicators by assessing HRQOL items in addition to demographic and clinical variables at baseline. Baseline HRQOL scores may be difficult to interpret and use in routine daily practice as a basis for treatment selection. Because the interpretation of dichotomized HRQOL variables is more comprehensible than interpretation of continuous variables, this method of presenting the data was chosen in this report.
With regard to treatment effect on disease-related symptoms in advanced NSCLC, hypofractionated palliative TRT is equivalent to normofractionated higher-dose TRT. 10 -13 Even though the treatment is palliative, there is a limited potential for long-term survival in localized disease. 12, 13 In the present study, which was restricted to stage IIIA and IIIB patients considered not suitable for curative radical TRT, some longterm survivors were observed in the higher-dose treatment arms. These few patients seem to be cured for their lung cancer, consistent with the Cochrane analysis, 13 indicating a modest increase of long-term survival in localized disease patients with good PS who are given high-dose fractionated palliative TRT.
In the study by Macbeth et al. 21 evaluating 39 Gy/13 fractions versus 17 Gy/2 fractions, the 1-and 2-year survival rates were 36 and 12% versus 31 and 9%, respectively, in favor of the prolonged fractionation scheme. This difference, persistent also at 3-and 4-year follow-up time, was observed in patients with good PS. However, there was no prognostic analysis in this study.
In a three-arm study comparing 50 Gy/25 fractions versus twice 20 Gy/5 fractions versus observation alone, Reinfuss et al. 22 observed 2-year survival rates of 12, 6, and 0%. In this study, survival beyond 2 years was not reported, and no prognostic factor analyses were performed. In a recent Dutch study comparing 30 Gy/10 fractions versus 16 Gy/two fractions, a 3-year survival rate of 5.6 versus 1.6% in favor of the higher-dose TRT was observed. 23 On the other hand, several randomized studies comparing hypofractionated TRT with higher-dose schedules 10,24 -28 did not reveal long-term survival differences. It is well known that the survival expectation for the majority of patients with advanced NSCLC is limited. Thus, palliative TRT should use a minimum of patient-time and radiotherapy resources for the community. In that respect, short-term hypofractionated palliative TRT is a good alternative. The challenge is to identify the minority of patients who might benefit from a higher-dose normofractionated palliative TRT schedule. In our multivariate analyses, appetite loss emerged as the most significant independent indicator for survival in this cohort of patients, whereas Karnofsky PS and weight loss did not reach significance. This finding was surprising because the prognostic significance of PS on survival is well documented in localized stage III disease. 29 -31 On the other hand, HRQOL items have been evaluated to a much lesser extent as prognostic factors in NSCLC. Kaasa et al. 5 and Ganz et al. 6 demonstrated the prognostic significance of patient-rated quality-of-life items. Subsequent studies using the European Organisation for Research and Treatment of Cancer core questionnaire and the QLQ-LC13 module (as in our study) confirmed baseline HRQOL data as valuable prognosticators. 32, 33 The study by Montazeri et al. 32 in 129 localized and metastatic lung cancer patients identified physical function, role function, global quality of life, pain, and fatigue as significant prognosticators in univariate analyses. In the subsequent multivariate analysis, only global quality of life was identified as a predictor for survival, along with disease stage and age. Langendijk et al. 8 investigated the prognostic role of baseline HRQOL scores in 198 patients treated with radical radiotherapy. In univariate analyses, appetite loss, fatigue, and global quality of life were found to have prognostic significance, whereas global quality of life remained the only significant prognostic HRQOL predictor in the multivariate analysis, along with classical clinical prognosticators such as N-stage and weight loss. In 206 advanced NSCLC patients receiving palliative chemotherapy, Herndon et al. 33 reported pain, appetite loss, fatigue, lung cancer symptoms, global quality of life, and physical function to be of prognostic significance in the univariate analysis. Here, pain was the only HRQOL item with independent prognostic value in the multivariate analysis.
To our knowledge, no previous trial restricted to stage III NSCLC disease treated with palliative TRT has investigated the influence of baseline HRQOL scores as prognostic factors. In our study, appetite loss was identified as the most powerful independent factor. Because any patient-reported loss of appetite is easily accessible, this variable seems valuable as a prognostic indicator used in routine clinical practice.
Retrospectively, when this palliative radiotherapy trial was performed, stage IIIB patients were most often considered beyond curative potential with radiotherapy alone. Since the trial was completed, our policy has changed, with more patients treated with high doses of 60 to 66 Gy with or without concomitant chemotherapy. The most valuable result from this secondary analysis of the stage III population is that it seems possible to cure some patients with even a palliative dose of TRT, although not with a hypofractionated schedule.
In conclusion, patients with no appetite loss and otherwise favorable prognostic factors should be treated with a higher-dose normofractionated or curative intended schedule (if they are candidates for TRT) and not shortterm hypofractionated TRT. Appetite loss at baseline seems to be one of the most important prognostic indicators in localized stage III NSCLC and should be assessed before TRT planning. The value of this prognostic factor in lung cancer patients given high-dose radiotherapy should be further explored in prospective randomized clinical trials. 
